Mark McClellan, MD, PhD, is a physician-economist who focuses on quality and value in health care, including payment and coverage reform, real-world evidence, more effective policies to support drug and device innovation, and initiatives to increase the impact of health care, public health, and social service programs on population health. His work on responding to the COVID-19 public health emergency spanned virus containment and testing strategies, reforming health care toward more resilient models of delivering care, and accelerating the development of therapeutics and vaccines, including a COVID-19 response roadmap. He is former commissioner of the U.S. Food and Drug Administration, and former administrator of the Centers for Medicare & Medicaid Services, where he developed and implemented major reforms in health policy. He has also served as a member of the President’s Council of Economic Advisors and as a Deputy Assistant Secretary for Economic Policy at the Department of the Treasury. He was previously Associate Professor of Economics with tenure at Stanford University. Dr. McClellan is an independent board member on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomIQ; chairs the National Academy of Medicine’s Leadership Consortium for a Value and Science-Driven Health System; co-chairs the Guiding Committee for the Health Care Payment Learning and Action Network; and serves as an advisor for Blackstone Life Sciences, Arsenal Capital Partners, and MITRE.